Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
$BHVN is up on the cancelled adcom news maybe because the last two cancelled adcoms by ON (that i can recall) led to approvals. This may be an outlier though https://t.co/2E1U2TUggc
$BHVN Biohaven Rises As FDA Cancels AdCom on Lead Drug https://t.co/UJCjUSSxOF
$BHVN no longer required to do an Adcom for SCA. The stock is up 12% premarket. https://t.co/9joSTzQXm4
The U.S. Food and Drug Administration has scrapped plans to convene an advisory committee to review Biohaven Pharmaceutical Holding Co.’s New Drug Application for troriluzole, an experimental therapy for spinocerebellar ataxia. The agency had scheduled the panel for May when it extended the Prescription Drug User Fee Act deadline, but now says the additional public meeting is unnecessary. Investors interpreted the change as a constructive signal for the filing. Biohaven shares rose about 12% in pre-market trading Friday, trading near $14.68. The company said it continues to work with the FDA as the application advances toward a final decision.
